Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats
Osteoporosis patients with chronic kidney disease (CKD) are becoming common in our superaging society. Renal dysfunction causes phosphorus accumulation in the circulating plasma and leads to the development of CKD-mineral bone disorder (MBD). We have previously reported that type III Pi transporter-...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2019/4194853 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564368333602816 |
|---|---|
| author | Yohei Asada Takeshi Takayanagi Tsukasa Kawakami Eisuke Tomatsu Atsushi Masuda Yasumasa Yoshino Sahoko Sekiguchi-Ueda Megumi Shibata Tomihiko Ide Hajime Niimi Eishin Yaoita Yusuke Seino Yoshihisa Sugimura Atsushi Suzuki |
| author_facet | Yohei Asada Takeshi Takayanagi Tsukasa Kawakami Eisuke Tomatsu Atsushi Masuda Yasumasa Yoshino Sahoko Sekiguchi-Ueda Megumi Shibata Tomihiko Ide Hajime Niimi Eishin Yaoita Yusuke Seino Yoshihisa Sugimura Atsushi Suzuki |
| author_sort | Yohei Asada |
| collection | DOAJ |
| description | Osteoporosis patients with chronic kidney disease (CKD) are becoming common in our superaging society. Renal dysfunction causes phosphorus accumulation in the circulating plasma and leads to the development of CKD-mineral bone disorder (MBD). We have previously reported that type III Pi transporter-overexpressing transgenic (Pit-1 TG) rats manifest phosphate (Pi)-dependent podocyte injury. In the present study, we explored the effect of risedronate on Pi-induced podocyte injury in vivo. Pit-1 TG rats and wild-type rats at 5 weeks old were divided into a risedronate-treated group and an untreated group. We subcutaneously administered 5 μg/kg body weight of risedronate or saline twice a week during the experimental period. Risedronate did not alter serum creatinine levels at 5, 8, and 12 weeks of age. However, electron microscopy images showed that thickening of the glomerular basement membrane was improved in the risedronate treatment group. Furthermore, immunostaining for podocyte injury markers revealed that both desmin- and connexin43-positive areas were smaller in the risedronate-treated group than in the untreated group, suggesting that bisphosphonates could rescue Pi-induced podocyte injury. In conclusion, our findings suggest that risedronate could maintain glomerular barrier function by rescuing Pi-induced podocyte injury. |
| format | Article |
| id | doaj-art-e626e3d2dc784acd9c8a2bfc164e6bca |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-e626e3d2dc784acd9c8a2bfc164e6bca2025-02-03T01:11:13ZengWileyInternational Journal of Endocrinology1687-83371687-83452019-01-01201910.1155/2019/41948534194853Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing RatsYohei Asada0Takeshi Takayanagi1Tsukasa Kawakami2Eisuke Tomatsu3Atsushi Masuda4Yasumasa Yoshino5Sahoko Sekiguchi-Ueda6Megumi Shibata7Tomihiko Ide8Hajime Niimi9Eishin Yaoita10Yusuke Seino11Yoshihisa Sugimura12Atsushi Suzuki13Department of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanJoint Research Support Promotion Facility, Center for Research Promotion and Support, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Anatomy, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Structural Pathology, Institute of Nephrology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 950-2102, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanDepartment of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi 470-1192, JapanOsteoporosis patients with chronic kidney disease (CKD) are becoming common in our superaging society. Renal dysfunction causes phosphorus accumulation in the circulating plasma and leads to the development of CKD-mineral bone disorder (MBD). We have previously reported that type III Pi transporter-overexpressing transgenic (Pit-1 TG) rats manifest phosphate (Pi)-dependent podocyte injury. In the present study, we explored the effect of risedronate on Pi-induced podocyte injury in vivo. Pit-1 TG rats and wild-type rats at 5 weeks old were divided into a risedronate-treated group and an untreated group. We subcutaneously administered 5 μg/kg body weight of risedronate or saline twice a week during the experimental period. Risedronate did not alter serum creatinine levels at 5, 8, and 12 weeks of age. However, electron microscopy images showed that thickening of the glomerular basement membrane was improved in the risedronate treatment group. Furthermore, immunostaining for podocyte injury markers revealed that both desmin- and connexin43-positive areas were smaller in the risedronate-treated group than in the untreated group, suggesting that bisphosphonates could rescue Pi-induced podocyte injury. In conclusion, our findings suggest that risedronate could maintain glomerular barrier function by rescuing Pi-induced podocyte injury.http://dx.doi.org/10.1155/2019/4194853 |
| spellingShingle | Yohei Asada Takeshi Takayanagi Tsukasa Kawakami Eisuke Tomatsu Atsushi Masuda Yasumasa Yoshino Sahoko Sekiguchi-Ueda Megumi Shibata Tomihiko Ide Hajime Niimi Eishin Yaoita Yusuke Seino Yoshihisa Sugimura Atsushi Suzuki Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats International Journal of Endocrinology |
| title | Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats |
| title_full | Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats |
| title_fullStr | Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats |
| title_full_unstemmed | Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats |
| title_short | Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats |
| title_sort | risedronate attenuates podocyte injury in phosphate transporter overexpressing rats |
| url | http://dx.doi.org/10.1155/2019/4194853 |
| work_keys_str_mv | AT yoheiasada risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT takeshitakayanagi risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT tsukasakawakami risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT eisuketomatsu risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT atsushimasuda risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT yasumasayoshino risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT sahokosekiguchiueda risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT megumishibata risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT tomihikoide risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT hajimeniimi risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT eishinyaoita risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT yusukeseino risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT yoshihisasugimura risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats AT atsushisuzuki risedronateattenuatespodocyteinjuryinphosphatetransporteroverexpressingrats |